Science and Research

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

This will be a phase I, single-center trial, including a total of 30 participants in two cohorts.
Both cohorts will be assigned to inhaled vaccination with MVA-SARS-2-ST.

Study details
Study-ID: NCT05226390
Study-ID: NCT05226390
DZL Disease Area: COPD
DZL Disease Area: COPD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - public
Funding: Externally - public
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 24.02.2022
Completion Date: 21.11.2023
Status: Closed
Status: Closed
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.